VYYRF - Voyageur Files Updated NI-43-101 Report on the Frances Creek Project & Completes SGS Canada Inc. Mine Site Visit for Advancement of PEA
(TheNewswire)
Calgary, Alberta - TheNewswire - November 2, 2020 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) (the"Company" or "Voyageur") is pleased to announcethe filing of its updated Frances Creek (FC) NI 43-101 TechnicalReport on SEDAR. Voyageur is working with SGS Canada Inc. (SGS) tocomplete a Preliminary Economic Assessment (PEA) and Pre-Feasibility(PF) study on its FC barium contrast project. SGS completed its sitevisit during the last week of October, 2020. This visit was a criticalstep forward in order to complete the PEA/Pre - Feasibility by Q12021.
Voyageur is currently working with SGS on the testingof the barium concentrates produced by the TOMRA - COM XRT 300 sortingmachine. The sorting machine is intended to be used to create thefirst stage concentrated barite located at the quarry site. Thistechnology will eliminate tailing ponds reduce water consumption andresult in a small environmental footprint.
Voyageur continues to focus on creating cash flow usingthird party minerals and manufacturing. Voyageur is working with thirdparties in Calgary and India who can manufacture the bariumradio-graphic contrast media products. Voyageur's immediate milestonesare to complete the PEA, PF, and initiate barium contrast sales withthird party manufacturers after receiving Health Canada approvals ofits products. Upon completion of these milestones, Voyageur will moveforward with the FC bulk sample project.
About Voyageur
Voyageur Pharmaceuticals Ltd. is a Canadian publiccompany listed on the TSX Venture Exchange under the trading symbolVM. Voyageur is focused on the development of barite, iodine, andfullerene Active Pharmaceutical Ingredient (API) minerals. Thenear-term focus is developing barium pharmaceutical products.Voyageur's goal is to initially generate positive cash flow fromoperations using third party GMP (Good Manufacturing Practices)pharmaceutical manufacturers. Ultimately, Voyageur has plans to buildall the required infrastructure to become 100% self-sufficient withall manufacturing. Voyageur owns a 100% interest in three bariumsulfate (barite) projects including two properties expected to besuitable in grade for the industrial barite marketplace, includinginterests in a high-grade iodine, lithium & bromine brine projectlocated in Utah, USA. Voyageur is moving forward with its businessplan of becoming the only fully integrated company in theradio-contrast pharmaceutical field, by controlling all primary inputcosts under the motto of: "From the Earth to the Bottle"
For further information, pleasecontact:
For Further Media Information or to set up aninterview, please contact:
Steven R. Livingston, Cell: (403) 471-1659 Steve@Vpharma.ca
www.voyageurpharmaceuticals.ca
Ron Love, CFO, Cell 403-818-6086, RonL @Vpharma.ca
Reader Advisory
Neither the TSXV nor its RegulationServices Provider (as that term is defined in the policies of theTSXV) accepts responsibility for the adequacy or accuracy of this newsrelease.
Cautionary NoteRegarding Forward-Looking Statements
This news release contains certainstatements or disclosures relating to the Company that are based onthe expectations of its management as well as assumptions made by andinformation currently available to the Company which may constituteforward-looking statements or information ("forward-lookingstatements") under applicable securities laws. All suchstatements and disclosures, other than those of historical fact, whichaddress activities, events, outcomes, results or developments that theCompany anticipates may or will occur in the future (in whole or inpart) should be considered forward-looking statement and unduereliance should not be placed on any such statements. In some cases,forward-looking statements can be identified by the use of the words"will", "intends", "believes","expects", forecasts", "anticipates","plans" and similar expressions.
In particular, but without limitingthe foregoing, this news release contains forward-looking statementspertaining to the following:, the feasibility and expectation of theCompany to bring its mining assets into production; the experience ofmanagement and directors of Voyageur and its pharmaceutical jointventure partner to execute on its business plan; the effectiveness ofthe TOMRA - COM XRT 300 sorting machine; the economics and risksassociated with its business plan; future operations and strategiesfor development, sales and distribution of mineral and pharmaceuticalproducts, including sales of barium contrast; the outcome and timingof its preliminary economic assessment and pre-feasibility;expectations, including timing, related to revenues and cash flow fromoperations; ability to successfully penetrate either domestic orforeign pharmaceutical markets; the amount, quality and cost of supplyof active pharmaceutical ingredients for potential pharmaceuticalproducts; anticipated registrations with Health Canada or similarforeign bodies for various pharmaceutical products the Company plansto develop, produce and sell; and the ability of the Company toattract investment capital to fund operations and capitalexpenditures.
The forward-looking statementscontained in this news release are made as of the date hereof and theCompany undertakes no obligations to update publicly or revise anyforward-looking statements, whether as a result of new information,future events or otherwise, unless so required by applicablesecurities laws.
Copyright (c) 2020 TheNewswire - All rights reserved.